Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Basilea Pharmaceutica AG
BPMUFCurrent price
52.83 USD
0 USD (0.00%)
Last closed
41.20 CHF
Company
www.basilea.com
ISIN
CH0011432447
Sector
Healthcare
Industry
Biotechnology
Exchange
SW
Capitalization
496 528 003 CHF
Yield for 12 month
+17.32 %
1Y
3Y
5Y
10Y
15Y
BPMUF
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
74.50 CHFP/E ratio
–Dividend Yield
–Current Year
+156 730 808 CHF
Last Year
+146 918 354 CHF
Current Quarter
+75 855 866 CHF
Last Quarter
+72 312 286 CHF
Current Year
+130 090 329 CHF
Last Year
+120 268 926 CHF
Current Quarter
+57 841 676 CHF
Last Quarter
+55 610 533 CHF
Key Figures BPMUF
1 year
3 years
5 years
10 years
EBITDA
-5 564 434 CHF
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-2.05 %
PEG Ratio
–
Return On Equity TTM
-4.10 %
Wall Street Target Price
74.50 CHF
Revenue TTM
148 168 152 CHF
Book Value
1.38 CHF
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-10.10 %
Dividend Yield
–
Gross Profit TTM
49 075 195 CHF
Earnings per share
-0.070 CHF
Diluted Eps TTM
-0.070 CHF
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-33.20 %
Profit Margin
-0.44 %
Dividend Analytics BPMUF
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History BPMUF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
11.04.2013
Forward Annual Dividend Yield
–
Last Split Factor
1039:1029
Payout Ratio
–
Last Split Date
13.03.2007
Dividend Date
–
Stock Valuation BPMUF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
11.68
Enterprise Value Revenue
3.76
Price Sales TTM
3.41
Enterprise Value EBITDA
24.28
Price Book MRQ
30.40
Financials BPMUF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BPMUF
For 52 weeks
31.82 CHF
47.68 CHF
50 Day MA
44.57 CHF
Shares Short Prior Month
–
200 Day MA
40.85 CHF
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart